Longeveron
LGVN • NASDAQ
Longeveron is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Stephen H. Willard, with a market cap of $26.9M.
CEOStephen H. Willard
Next Earnings
Upcoming earnings announcement for Longeveron
Date
Thursday, May 7, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.17
Revenue Estimate
$327.6K
Earnings History
Past 12 earnings reports for Longeveron
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 17, 2026 | Q4 2025 | -$0.22Est: -$0.38 | +42.1% | $365.0KEst: $106.2K | +243.7% | — |
| Nov 4, 2025 | Q3 2025 | -$0.39Est: -$0.25 | -56.0% | $137.0KEst: $282.8K | -51.6% |  10-Q |
| Aug 13, 2025 | Q2 2025 | -$0.33Est: -$0.35 | +5.7% | $316.0KEst: $414.7K | -23.8% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.34 | — | $381.0KEst: $600.3K | -36.5% | 10-Q |
| Feb 28, 2025 | Q4 2024 | -$0.27Est: -$0.36 | +25.0% | $603.0KEst: $660.0K | -8.6% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.34Est: -$0.44 | +22.7% | $773.0KEst: $400.0K | +93.3% | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$1.83Est: -$1.05 | -74.3% | $468.0KEst: $360.0K | +30.0% | 10-Q |
| May 14, 2024 | Q1 2024 | -$1.61Est: -$2.00 | +19.5% | $548.0KEst: $100.0K | +448.0% | 10-Q |
| Feb 27, 2024 | Q4 2023 | -$2.50Est: -$2.10 | -19.0% | $63.0KEst: $210.0K | -70.0% | 10-K/A |
| Nov 10, 2023 | Q3 2023 | -$2.80Est: -$2.20 | -27.3% | $150.0KEst: $200.0K | -25.0% | — |
| Aug 11, 2023 | Q2 2023 | -$2.70Est: -$2.50 | -8.0% | $217.0KEst: $400.0K | -45.8% | 10-Q |
| May 12, 2023 | Q1 2023 | -$2.20Est: -$2.10 | -4.8% | $279.0KEst: $300.0K | -7.0% | — |